103 related articles for article (PubMed ID: 7528557)
1. Benign prostatic hyperplasia: it is a premalignant lesion?
Grignon D; Sakr W
In Vivo; 1994; 8(3):415-8. PubMed ID: 7528557
[TBL] [Abstract][Full Text] [Related]
2. [Prostate gland-transition zone lesions. Etiology, growth regulation, growth factors, genetic changes].
Pavelić J; Zeljko Z
Lijec Vjesn; 2002; 124(6-7):211-9. PubMed ID: 19658339
[TBL] [Abstract][Full Text] [Related]
3. [Premalignant and benign lesions in nodules of adenomatous hyperplasia].
Miján Ortiz JL; Fernández Rodríguez A; Fernández Ruiz PL; de la Fuente Serrano A; Nogales Fernández F; Zuluaga Gómez A
Arch Esp Urol; 1996 Sep; 49(7):684-7. PubMed ID: 9020004
[TBL] [Abstract][Full Text] [Related]
4. Alpha-methylacyl-CoA racemase (P504S) expression in evolving carcinomas within benign prostatic hyperplasia and in cancers of the transition zone.
Leav I; McNeal JE; Ho SM; Jiang Z
Hum Pathol; 2003 Mar; 34(3):228-33. PubMed ID: 12673556
[TBL] [Abstract][Full Text] [Related]
5. Atypical adenomatous hyperplasia of the prostate: a premalignant lesion?
Cheng L; Shan A; Cheville JC; Qian J; Bostwick DG
Cancer Res; 1998 Feb; 58(3):389-91. PubMed ID: 9458077
[TBL] [Abstract][Full Text] [Related]
6. Premalignant lesions of prostate and their association with nodular hyperplasia and carcinoma prostate.
Rekhi B; Jaswal TS; Arora B
Indian J Cancer; 2004; 41(2):60-5. PubMed ID: 15318010
[TBL] [Abstract][Full Text] [Related]
7. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
Hammarsten J; Högstedt B
Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
[TBL] [Abstract][Full Text] [Related]
8. Associations among benign prostate hypertrophy, atypical adenomatous hyperplasia and latent carcinoma of the prostate.
Stamatiou K; Alevizos A; Natzar M; Mihas C; Mariolis A; Michalodimitrakis E; Sofras F
Asian J Androl; 2007 Mar; 9(2):229-33. PubMed ID: 16751999
[TBL] [Abstract][Full Text] [Related]
9. Relationship between atypical adenomatous hyperplasia (AAH), prostatic intraepithelial neoplasia (PIN) and prostatic adenocarcinoma.
Helpap B; Bonkhoff H; Cockett A; Montironi R; Troncoso P; Waters D; Bostwick D
Pathologica; 1997 Jun; 89(3):288-300. PubMed ID: 9270265
[TBL] [Abstract][Full Text] [Related]
10. Changes in keratin expression during the development of benign prostatic hyperplasia.
Xue Y; Smedts F; Umbas R; Aalders TW; Debruyne FM; de la Rosette JJ; Schalken JA
Eur Urol; 1997; 32(3):332-8. PubMed ID: 9358223
[TBL] [Abstract][Full Text] [Related]
11. Is there a relationship between benign prostatic hyperplasia and prostatic cancer?
Pagano F; Zattoni F; Vianello F; Piazza R; Capitanio G
Eur Urol; 1991; 20 Suppl 1():31-5. PubMed ID: 1722159
[TBL] [Abstract][Full Text] [Related]
12. The significance of atypical adenomatous hyperplasia and prostatic intraepithelial neoplasia for the development of prostate carcinoma. An update.
Helpap BG; Bostwick DG; Montironi R
Virchows Arch; 1995; 426(5):425-34. PubMed ID: 7543337
[TBL] [Abstract][Full Text] [Related]
13. Genetic analysis of prostatic atypical adenomatous hyperplasia (adenosis).
Doll JA; Zhu X; Furman J; Kaleem Z; Torres C; Humphrey PA; Donis-Keller H
Am J Pathol; 1999 Sep; 155(3):967-71. PubMed ID: 10487854
[TBL] [Abstract][Full Text] [Related]
14. Boundary in the pathologic evaluation of premalignant prostatic lesions.
Algaba F
Pathol Res Pract; 1995 Sep; 191(9):856-9. PubMed ID: 8606865
[TBL] [Abstract][Full Text] [Related]
15. Associations between polymorphisms in the steroid 5-alpha reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer.
Salam MT; Ursin G; Skinner EC; Dessissa T; Reichardt JK
Urol Oncol; 2005; 23(4):246-53. PubMed ID: 16018939
[TBL] [Abstract][Full Text] [Related]
16. Limitations of transition zone needle biopsy findings in the prediction of transition zone cancer and tissue composition of benign nodular hyperplasia.
McNeal J; Noldus J
Urology; 1996 Nov; 48(5):751-6. PubMed ID: 8911519
[TBL] [Abstract][Full Text] [Related]
17. Is transition zone biopsy valuable in benign prostatic hyperplasia patients with serum prostate-specific antigen >10 ng/ml and prior negative peripheral zone biopsy?
Abdel-Khalek M; Sheir KZ; El-Baz M; Ibrahiem el-H
Scand J Urol Nephrol; 2005; 39(1):49-55. PubMed ID: 15764271
[TBL] [Abstract][Full Text] [Related]
18. Expression of androgen receptor and growth factors in premalignant lesions of the prostate.
Harper ME; Glynne-Jones E; Goddard L; Mathews P; Nicholson RI
J Pathol; 1998 Oct; 186(2):169-77. PubMed ID: 9924433
[TBL] [Abstract][Full Text] [Related]
19. Preneoplastic lesions of the prostate-clinical, pathological and molecular biological aspects.
Nasir A; Copeland J; Gillespie JW; Chughtai OR; Andrawis R; Kaiser HE; Manyak MJ
In Vivo; 2002; 16(6):557-66. PubMed ID: 12494901
[TBL] [Abstract][Full Text] [Related]
20. The impact of systematic prostate biopsy on prostate cancer incidence in men with symptomatic benign prostatic hyperplasia undergoing transurethral resection of the prostate.
Ornstein DK; Rao GS; Smith DS; Andriole GL
J Urol; 1997 Mar; 157(3):880-3; discussion 883-4. PubMed ID: 9072591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
